The Synthetic Organs, Tissues and Combination Products mainly include the following artificial organs, organ assistive devices, combination products (device + biological or pharmaceutical products), materials-based devices, biocompatibility technologies, and infection-inhibiting devices.
Artificial Organ, Organ Assistive Devices
Allografts (Tissue-engineered Products)
Batteries for Implants
Glucose Monitoring Products
Insulin Pumps/Delivery Systems
Minimally Invasive Implants (Minimally Invasive Technologies)
Tissue Engineering Technologies
Device Immunosuppressive Technologies
New Biomimetic Surface Technologies
Combination Products (Device + Biological/Pharmaceutical Products)
Other Drug Delivering Devices
Advanced Nitinol-Based Devices
Advanced Polymer-Based Devices
Surface-Modified Infection-Resistant Devices
Both the artificial organs and organ/assistive devices, and combination device/drug/biological products are likely to produce significant new medical device developments within the five years as it continues to be driven by the limited availability of donor organs and tissue for transplantation.
In the technology area of artificial organs and organ-assistive products, there are relatively strong possibilities in advances for tissue-engineered products, neurosensory devices, glucose-monitoring products, electrostimulation-based devices, and prosthetic limbs with advanced bio-integration properties. The results also suggest that new insulin delivery systems, new types of stents, and new joint replacements may also be developed during this time period covered by the next five-year forecast. The main constraints include major uncertainties about the source of cells for tissue engineered and other bio-based synthetic organs, biocompatibility of implants, complexity of biointegration, and long-term durability, whereas potential issues included questions about impact of new delivery systems on safety and efficacy of pharmaceuticals.
The global organ preservation solutions market by solution (Viaspan, Custodiol HTK Solution, Renograf, Hypothermosol, Perfadex, Lifor, Human bioSystem solution, siRNA Transplant solution, etc.), and its preservation techniques (hypothermic perfusion preservation, static cold storage, etc.) expected to reach US$ 254 million by 2021, growing at CAGR 13% over the forecast period 2017-2021.
The global tissue engineered skin substitutes market segmentation is based on product types (acellular, cellular allogeneic, cellular autologous), and its applications (burn injury, diabetic, vascular ulcer) expected to reach US$ 16 billion by 2021, growing at CAGR 2.4% over the forecast period 2017-2021.
Reference: Herman and Devey, Future trends in medical device technologies: A ten-year forecast.